BioCardia Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

false 0000925741 0000925741 2024-10-28 2024-10-28

 

 

 

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): October 28, 2024

 

 

 

 

Registrant’s telephone number, including area code: (650) 226-0120

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 

 

 

 

Securities registered pursuant to Section 12(b) of the Act:

 

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter) ☐

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 8.01   Other Events.

 

On October 28, 2024, BioCardia, Inc. (the “Company”) issued a press release announcing the completion of its last protocol specified follow-up visit in CardiAMP HF, a prospective, randomized double-blinded, placebo procedure controlled, multi-center pivotal clinical trial.

 

A copy of the press release is attached hereto as Exhibit 99.1.

 

Item 9.01   Financial Statements and Exhibits.
 
(d) Exhibits
 

 
 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.